QUTENZA

This brand name is authorized in Austria, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, South Africa, Spain, UK.

Active ingredients

The drug QUTENZA contains one active pharmaceutical ingredient (API):

1	Capsaicin UNII S07O44R1ZM - CAPSAICIN
	Capsaicin, or 6-nonenamide, N-[(4-hydroxy-3-methoxyphenyl) methyl]-8-methyl, (6E), is a highly selective agonist for the transient receptor potential vanilloid 1 receptor (TRPV1). The initial effect of capsaicin is the activation of TRPV1-expressing cutaneous nociceptors, which results in pungency and erythema due to the release of vasoactive neuropeptides.
	Read more about Capsaicin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QUTENZA Cutaneous patch	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N01BX04	Capsaicin	N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BX Other local anesthetics
Discover more medicines within N01BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5941-MEE-0221
EE	Ravimiamet	1420647, 1420658
ES	Centro de información online de medicamentos de la AEMPS	09524001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	094812
FR	Base de données publique des médicaments	66525842
GB	Medicines & Healthcare Products Regulatory Agency	173200
IT	Agenzia del Farmaco	040111015, 040111027
LT	Valstybinė vaistų kontrolės tarnyba	1037884, 1037885
NL	Z-Index G-Standaard, PRK	94099
PL	Rejestru Produktów Leczniczych	100052637
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54778001, W54778002
ZA	Health Products Regulatory Authority	45/4/1099